It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Evidence suggests that people at Clinical High Risk for Psychosis (CHR) have a blunted cortisol response to stress and altered mediotemporal activation during fear processing, which may be neuroendocrine–neuronal signatures of maladaptive threat responses. However, whether these facets are associated with each other and how this relationship is affected by cannabidiol treatment is unknown. We examined the relationship between cortisol response to social stress and mediotemporal function during fear processing in healthy people and in CHR patients. In exploratory analyses, we investigated whether treatment with cannabidiol in CHR individuals could normalise any putative alterations in cortisol-mediotemporal coupling. 33 CHR patients were randomised to 600 mg cannabidiol or placebo treatment. Healthy controls (n = 19) did not receive any drug. Mediotemporal function was assessed using a fearful face-processing functional magnetic resonance imaging paradigm. Serum cortisol and anxiety were measured immediately following the Trier Social Stress Test. The relationship between cortisol and mediotemporal blood-oxygen-level-dependent haemodynamic response was investigated using linear regression. In healthy controls, there was a significant negative relationship between cortisol and parahippocampal activation (p = 0.023), such that the higher the cortisol levels induced by social stress, the lower the parahippocampal activation (greater deactivation) during fear processing. This relationship differed significantly between the control and placebo groups (p = 0.033), but not between the placebo and cannabidiol groups (p = 0.67). Our preliminary findings suggest that the parahippocampal response to fear processing may be associated with the neuroendocrine (cortisol) response to experimentally induced social stress, and that this relationship may be altered in patients at clinical high risk for psychosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 King’s College London, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
2 Utrecht University, Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht, The Netherlands (GRID:grid.5477.1) (ISNI:0000000120346234)
3 King’s College London, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); South London and Maudsley NHS Foundation Trust, National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre (BRC), London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839)
4 King’s College London, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
5 Cambridgeshire and Peterborough NHS Foundation Trust, CAMEO Early Intervention Service, Cambridge, UK (GRID:grid.450563.1) (ISNI:0000 0004 0412 9303)
6 King’s College London, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); University of Roehampton, Department of Psychology, London, UK (GRID:grid.35349.38) (ISNI:0000 0001 0468 7274); Mount Sinai Hospital, Icahn School of Medicine, New York, USA (GRID:grid.416167.3) (ISNI:0000 0004 0442 1996)
7 King’s College London, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); South London and Maudsley NHS Foundation Trust, National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre (BRC), London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839); South London and Maudsley NHS Foundation Trust, Outreach and Support in South London (OASIS) Service, London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839)